PMID- 23162107
OWN - NLM
STAT- MEDLINE
DCOM- 20130418
LR  - 20211203
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 66
IP  - 3
DP  - 2013 Mar
TI  - Over-expression of phosphorylated mammalian target of rapamycin is associated 
      with poor survival in oesophageal adenocarcinoma: a tissue microarray study.
PG  - 224-8
LID - 10.1136/jclinpath-2012-201173 [doi]
AB  - BACKGROUND: Protein kinase mammalian target of rapamycin (mTOR) is an important 
      downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt signalling 
      pathway. In several tumour types, phosphorylated mTOR (p-mTOR) over-expression is 
      an independent prognostic marker for poor survival. However, p-mTOR expression 
      has not been assessed in oesophageal adenocarcinoma (OAC). MATERIALS AND METHODS: 
      Tumour cores of 154 patients with OAC were included in a tissue microarray (TMA). 
      Scoring criteria were based on p-mTOR staining intensity. RESULTS: 147 (95.5%) 
      patients were available for immunohistochemical evaluation. Over-expression of 
      p-mTOR was detected in 29 (19.7%) tumours, whereas 118 (80.3%) patients showed 
      negative expression. Over-expression was significantly associated with poor 
      overall survival in univariate analysis (HR 1.648; 95% CI 1.019 to 2.664; 
      p=0.042). Median survival was 21.2 months in patients with p-mTOR over-expression 
      and 29.0 in the negative p-mTOR group (p=0.040). In addition, a trend towards 
      p-mTOR over-expression and vasoinvasive growth was seen (p=0.057). In 
      multivariate analysis, including clinical and pathological variables (p<0.10), 
      only T-stage (HR 2.795; 95% CI 1.343 to 5.813; p=0.006) and differentiation grade 
      (HR 2.198; 95% CI 1.353 to 3.570; p=0.001) were independent prognostic markers of 
      poor survival. CONCLUSION: p-mTOR over-expression was detected in 19.7% of 
      patients with OAC and was associated with poor overall survival.
FAU - Prins, Margriet J D
AU  - Prins MJ
AD  - Department of Surgery, University Medical Center Utrecht, Utrecht, The 
      Netherlands.
FAU - Verhage, Roy J J
AU  - Verhage RJ
FAU - Ruurda, Jelle P
AU  - Ruurda JP
FAU - ten Kate, Fiebo J W
AU  - ten Kate FJ
FAU - van Hillegersberg, Richard
AU  - van Hillegersberg R
LA  - eng
PT  - Journal Article
DEP - 20121116
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adenocarcinoma/*metabolism/mortality/secondary
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Esophageal Neoplasms/*metabolism/mortality/pathology
MH  - Female
MH  - Humans
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Phosphorylation
MH  - Prognosis
MH  - Survival Rate
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Tissue Array Analysis/methods
EDAT- 2012/11/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2012/11/20 06:00
PHST- 2012/11/20 06:00 [entrez]
PHST- 2012/11/20 06:00 [pubmed]
PHST- 2013/04/20 06:00 [medline]
AID - jclinpath-2012-201173 [pii]
AID - 10.1136/jclinpath-2012-201173 [doi]
PST - ppublish
SO  - J Clin Pathol. 2013 Mar;66(3):224-8. doi: 10.1136/jclinpath-2012-201173. Epub 
      2012 Nov 16.